Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 4/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30579362 | 1.00 | CYP3A4 (0.54) | CYP3A4ALDH1A1CYP1A2HPGDSCYP2A6 | |
| SCHEMBL16568967 | 0.84 | CYP3A4 (0.51) | CYP3A4ALDH1A1CYP1A2HPGDSCYP2A6 | |
| SCHEMBL30872899 | 0.84 | CYP3A4 (0.51) | CYP3A4ALDH1A1CYP1A2HPGDSCYP2A6 | |
| SCHEMBL2822471 | 0.81 | RAB9A (0.55) | ALDH1A1HPGDSTNIK | |
| SCHEMBL6235520 | 0.80 | PDPK1 (0.42) | MAPK8MAPK9GSK3BROCK1AXL | |
| SCHEMBL2318425 | 0.78 | CYP3A4 (0.59) | CYP3A4ALDH1A1CYP1A2HPGDSCYP2A6 | |
| SCHEMBL26547900 | 0.77 | CHEK1 (0.55) | CYP3A4ALDH1A1CYP1A2HPGDSCYP2A6 | |
| SCHEMBL3078162 | 0.76 | CYP3A4 (0.89) | CYP3A4ALDH1A1CYP1A2HPGDSCYP2A6 | |
| SCHEMBL28207587 | 0.76 | ALDH1A1 (0.61) | CYP3A4ALDH1A1CYP1A2HPGDSCYP2A6 | |
| SCHEMBL20575392 | 0.75 | CYP3A4 (0.59) | CYP3A4ALDH1A1CYP1A2HPGDSCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-9499519-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012006203-A1 | N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, FGFR3, FGFR1 | CYP3A4 4611/4885ALDH1A1 3567/4885CYP1A2 4760/4885 |
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | CYP3A4 2215/4885ALDH1A1 2674/4885CYP1A2 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.